User profiles for Torsten Gerriet Blum
Dr. Torsten BlumKlinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring Verified email at helios-gesundheit.de Cited by 2934 |
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …
…, SM Huhn, J Richter, U Neff, TG Blum… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …
ESR/ERS statement paper on lung cancer screening
HU Kauczor, AM Baird, TG Blum, L Bonomo… - European …, 2020 - Springer
In Europe, lung cancer ranks third among the most common cancers, remaining the biggest
killer. Since the publication of the first European Society of Radiology and European …
killer. Since the publication of the first European Society of Radiology and European …
[HTML][HTML] Morphometrical analysis of transbronchial cryobiopsies
The recent introduction of bronchoscopically recovered cryobiopsy of lung tissue has opened
up new possibilities in the diagnosis of neoplastic and non-neoplastic lung diseases in …
up new possibilities in the diagnosis of neoplastic and non-neoplastic lung diseases in …
[HTML][HTML] Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series
S Griff, N Schönfeld, W Ammenwerth, TG Blum… - BMC pulmonary …, 2014 - Springer
Background Due to the small amount of alveolar tissue in transbronchial biopsy (TBB) by
forceps, the diagnosis of diffuse, parenchymal lung diseases (DPLD) is inherently problematic, …
forceps, the diagnosis of diffuse, parenchymal lung diseases (DPLD) is inherently problematic, …
[HTML][HTML] Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry
PURPOSE Although NRG1 fusions are oncogenic drivers across multiple tumor types
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …
European Respiratory Society guideline on various aspects of quality in lung cancer care
This European Respiratory Society guideline is dedicated to the provision of good quality
recommendations in lung cancer care. All the clinical recommendations contained were based …
recommendations in lung cancer care. All the clinical recommendations contained were based …
[HTML][HTML] Autoimmune disorders and paraneoplastic syndromes in thymoma
TG Blum, D Misch, J Kollmeier, S Thiel… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Thymomas are counted among the rare tumour entities which are associated with
autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other …
autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other …
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer–A multicenter observational analysis
N Frost, K Unger, TG Blum, D Misch, S Kurz, H Lüders… - Lung Cancer, 2023 - Elsevier
Introduction Checkpoint-inhibitor pneumonitis (CIP) represents a major immune-related
adverse event (irAE) in patients with lung cancer. We aimed for the clinical characterization, …
adverse event (irAE) in patients with lung cancer. We aimed for the clinical characterization, …
[HTML][HTML] Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their …
…, J Chorostowska-Wynimko, TG Blum… - ERJ Open …, 2023 - Eur Respiratory Soc
7 years on from the European Society of Radiology (ESR)/European Respiratory Society (ERS)
white paper on lung cancer screening, which recommended low-dose computed …
white paper on lung cancer screening, which recommended low-dose computed …
NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.
9081 Background: NRG1 fusions are potentially actionable driver events enriched in NSCLCs,
particularly invasive mucinous adenocarcinomas (IMAs). These fusions activate HER3/…
particularly invasive mucinous adenocarcinomas (IMAs). These fusions activate HER3/…